This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The analysis was based on a randomised controlled trial carried out in a single centre (Morriston Hospital, Swansea NHS Trust, UK). The unit of randomisation was not reported. Patients in the PRCS group received autotransfusion of wound drainage if the volume was greater than 125ml post-operatively and were also transfused with allogeneic blood if their haemoglobin fell below the preset trigger (9g dl^-1) after autotransfusion. Patients in the control group received allogeneic blood at the same transfusion trigger. Haemoglobin concentrations were measured on days 1, 2, 3, 4, and 7. Some outcomes were measured up to 6 months after surgery, suggesting that follow-up extended for this length of time. The authors did not report any loss to follow-up. Adverse events were considered by a blind assessor to determine whether they were related to the transfusion.
Analysis of effectiveness
Analysis was based on intention to treat. In addition to the intention to treat results, the authors also reported some results according to actual treatment received. Primary health outcomes were: length of stay, peri-operative and posthospital discharge infection rates, adverse events, and wound healing rates. The authors reported that patients in the two groups were 'comparable' and their comparability in terms of anaesthetic used and prosthesis used was discussed. A total of 18 patients in the treatment group did not receive PRCS.
Effectiveness results
The authors did not report specific values for many primary outcome measures. However, they did report that "there was no significant difference in length of stay, wound healing, serious adverse events or mortality" and that there was no difference in post-operative mean haemoglobin concentration between the groups. The incidence of allogeneic blood transfusion was 7% in the PRCS group and 28% in the control group, (p<0.001). The authors also found fewer readmissions to hospital, (p<0.008), and visits to GPs, (p<0.043), in patients in the PCRS group.
Clinical conclusions
The authors concluded that "a decrease in allogeneic blood could be achieved by using PRCS".
Measure of benefits used in the economic analysis
The authors estimated quality of life using the EuroQol EQ-5D the data being collected by research nurses. Valuations were obtained at 0, 1, 4 and 12 weeks (with week 0 presumably representing the time of treatment). No further details were reported.
Direct costs
A perspective for the costing analysis was not reported although costs relating to the hospital appear to have been estimated. A time horizon was not reported however the authors did state that this analysis was short term. In practice the study appears to have been concerned with the immediate costs associated with treatment. The time frame for readmission and further GP consultations was not given. Therefore, it is not possible to assess whether discounting should have been applied to these estimates. The authors reported that the end of study mortality in some cases indicated a 2-year follow-up. This estimate suggests that discounting should have been used. The authors reported costs per patient. Therefore, volumes of one unit appear to have been assumed, with the authors then reporting unit costs (certainly no quantities were reported separately). Direct costs comprised allogeneic blood, staff time, capital and
